{"id":616885,"date":"2022-09-16T22:28:01","date_gmt":"2022-09-16T22:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616885"},"modified":"2022-09-16T22:28:01","modified_gmt":"2022-09-16T22:28:01","slug":"pompe-disease-market-to-grow-rapidly-during-the-forecast-period-2032-delveinsight-key-companies-amicus-therapeutics-atgaa-aro-biotherapeutics-abx1100-maze-therapeutics-mze001","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pompe-disease-market-to-grow-rapidly-during-the-forecast-period-2032-delveinsight-key-companies-amicus-therapeutics-atgaa-aro-biotherapeutics-abx1100-maze-therapeutics-mze001_616885.html","title":{"rendered":"Pompe Disease Market to Grow Rapidly During the Forecast Period (2032) – DelveInsight | Key Companies – Amicus Therapeutics (AT-GAA), Aro Biotherapeutics (ABX1100), Maze Therapeutics (MZE001)"},"content":{"rendered":"
\n
\"Pompe<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight\u2019s assessment, globally, nearly 15+ key pharma and biotech companies are working in the Pompe Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n

The Pompe Disease Market is expected to grow in the coming years owing to the increasing incidence and the expected launch of emerging therapies.<\/em><\/p>\n

DelveInsight’s “Pompe Disease Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pompe Disease Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Pompe Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Pompe<\/p>\n

Pompe Disease: An Overview<\/strong><\/p>\n

Pompe disease, also known as glycogen storage disease type II (GSD II) or “acid maltase deficiency,” is caused by the absence or deficiency of acid alpha-glucosidase (GAA), a lysosomal enzyme that is responsible for the cleavage of the α-1, 4- and α-1, 6-glycosidic bonds of glycogen to glucose.<\/p>\n

Pompe disease comes at different ages and with different degrees of severity. The severity of the clinical presentations, the tissue involvement, and the age of onset generally correlate well with the nature of the mutation and the degree of residual enzyme activity. <\/em><\/p>\n

Pompe Disease Market Key Facts<\/strong><\/p>\n

• As per Delveinsight’s estimates, a total of 2,556+<\/strong> Pompe disease cases were reported in 2017.<\/em><\/p>\n

• Among the EU5 countries, Germany<\/strong> had the highest prevalent population of Pompe Disease with 816 cases<\/strong>, followed by France<\/strong>, which had a prevalence of 683 cases<\/strong> in 2017. On the other hand, Spain<\/strong> had the lowest prevalent population of 496 cases<\/strong> in 2017<\/em><\/p>\n

• As per Delveinsight’s estimates, in 2017, the prevalent cases of Infantile-onset Pompe Disease and Late-onset Pompe Disease in Japan were found to be 150<\/strong> and 920<\/strong> respectively, and are expected to increase by 2032.<\/em><\/p>\n

Pompe Disease Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Pompe Disease market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.<\/p>\n

The report details the Pompe Disease market trend<\/strong> for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n

Pompe Disease Epidemiology<\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n

Pompe Disease Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pompe Disease market<\/strong> or expected to get launched during the study period. The analysis covers Pompe Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. <\/p>\n

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Pompe Disease Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Key Developments in the Pompe Disease Therapeutics Market<\/strong><\/p>\n

• On September 15, 2022, Aro Biotherapeutics<\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> granted Rare Pediatric Drug (RPD) designation<\/strong> for ABX1100<\/strong>, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in muscle, for the treatment of Pompe disease.<\/em><\/p>\n

• On August 31, 2022, Maze Therapeutics<\/strong> announced that the US FDA<\/strong> had granted Orphan Drug Designation<\/strong> to MZE001<\/strong>, the company’s investigational product for treating Pompe disease. <\/em><\/p>\n

• In May 2021, Amicus Therapeutics<\/strong> announced the completion of a successful Type B Pre-Biologics License Application (BLA) meeting with the US FDA<\/strong> for AT-GAA (cipaglucosidase alfa co-administered with miglustat), for the treatment of Pompe disease.<\/em><\/p>\n

Learn how the Pompe Disease Market will evolve in the coming years:
https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-market<\/a><\/strong><\/p>\n

Pompe Disease Therapeutics Analysis<\/strong><\/p>\n

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years.<\/p>\n

There are approx. 15+ key companies<\/strong> which are developing therapies for Pompe Disease. Currently, Amicus Therapeutics<\/strong> is leading the Pompe Disease therapeutics market with its drug candidates in the most advanced stage of clinical development.<\/em><\/p>\n

Some of the key companies in the Pompe Disease Therapeutic Market include<\/strong><\/p>\n

• Asklepios Biopharmaceutical<\/p>\n

• Astellas Pharma Inc<\/p>\n

• BioMarin Pharmaceutical<\/p>\n

• Amicus Therapeutics<\/p>\n

• Spark Therapeutics<\/p>\n

• Maze Therapeutics<\/p>\n

• Denali Therapeutics<\/p>\n

• Rocket Pharmaceuticals<\/p>\n

• Audentes Therapeutics<\/p>\n

• Sanofi<\/p>\n

• Actus<\/p>\n

• Roche <\/p>\n

• Valerion <\/p>\n

And many others<\/p>\n

Pompe Disease Emerging Drugs Covered in the report include:<\/strong><\/p>\n

• AT-GAA: Amicus Therapeutics<\/p>\n

• SPK-3006: Spark Therapeutics<\/p>\n

• Avalglucosidase <\/p>\n

• VAL-1221<\/p>\n

• ACTUS-101<\/p>\n

• AT845<\/p>\n

And many more<\/strong><\/p>\n

Further product details are provided in the report. Download the sample Report to get more detailed insights at:
<\/strong>https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-market<\/a><\/strong><\/p>\n

Table of Content (TOC)<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary <\/p>\n

3. Pompe Disease Competitive Intelligence Analysis<\/p>\n

4. Pompe Disease Market Overview at a Glance<\/p>\n

5. Pompe Disease Disease Background and Overview<\/p>\n

6. Pompe Disease Patient Journey<\/p>\n

7. Pompe Disease Epidemiology and Patient Population<\/p>\n

8. Pompe Disease Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Pompe Disease Unmet Needs<\/p>\n

10. Key Endpoints of Pompe Disease Treatment<\/p>\n

11. Pompe Disease Marketed Products<\/p>\n

12. Pompe Disease Emerging Therapies<\/p>\n

13. Pompe Disease Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Pompe Disease Market Outlook (7 major markets)<\/p>\n

16. Pompe Disease Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Pompe Disease Market.<\/p>\n

18. Pompe Disease Market Drivers<\/p>\n

19. Pompe Disease Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/strong><\/em><\/p>\n

Download Sample PDF Report – https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-market<\/a><\/strong><\/p>\n

 <\/p>\n

About DelveInsight
<\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n

Other Trending Healthcare Reports by DelveInsight<\/strong><\/p>\n

Cardiopulmonary Autotransfusion Devices Market
<\/a><\/strong>“Cardiopulmonary Autotransfusion Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Cardiopulmonary Autotransfusion Devices. It also covers the latest breakthroughs, collaboration, innovations, emerging devices, and key companies working in the global Cardiopulmonary Autotransfusion Devices market. <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Shruti Thakur
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NV
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, nearly 15+ key pharma and biotech companies are working in the Pompe Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,425,426,417,404],"tags":[],"class_list":["post-616885","post","type-post","status-publish","format-standard","hentry","category-Business","category-Finance","category-Financial-Market","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=616885"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616885\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=616885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=616885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=616885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}